NEW YORK (GenomeWeb) – LGC said today that it has acquired Lucigen, a developer, manufacturer, and supplier of molecular biology enzymes, reagents, and kits, for an undisclosed amount.

Founded in 1998, Lucigen currently employs over 65 people at its Middleton, Wisconsin site. It has an extensive portfolio of life science products including next-generation sequencing kits, enzymes, competent cells, and cloning systems, targeting fast growth applications in clinical diagnostics, drug discovery, synthetic biology, and gene editing.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.